H. Necrotizing PancreatitisThe published guideline made special reference to the use of antibiotics innecrotizing pancreatitis:The administration of prophylactic antibiotics to patients with severe necrotizingpancreatitis prior to the diagnosis of infection is not recommendedBroad-spectrum antibiotic therapy has been used by some clinicians for thetreatment of patients with necrotizing pancreatitis, in an effort to prevent aninfection in the inflammatory phlegmon and thereby improve patient outcome. Ina guideline on the management of severe pancreatitis, however, the authorsconcluded that this approach was not justified on the basis of available data. Ameta-analysis of trials performed in this area have shown that positive resultswere attributable to poor study design and that well-designed studies did notdemonstrate benefit .This practice is not recommended without clinicalor culture evidence of an established infection in patients with necrotizingpancreatitis. In those patients with established pancreatic infection, the agentsrecommended for use with community-acquired infection of higher severity andhealth care–associated infection are the preferred agents. Because of thedifficulty of achieving adequate source control in patients with infected pancreaticand peripancreatic phelgma, a longer duration of therapy may be needed.References:1. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, BaronEJ, O’Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S,Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis andmanagement of complicated intra-abdominal infections in adults andchildren: <strong>Guidelines</strong> by the Surgical Infection Society and the InfectiousDiseases Society of America. Clin Infect Dis 2010;50:133-1642. <strong>UW</strong>HC <strong>Antimicrobial</strong> <strong>Use</strong> <strong>Guidelines</strong> 20 th Edition. Appendix B. SurgicalProphylaxis. 2009.
Appendix N: <strong>Antimicrobial</strong> Duration of TherapyThe information contained in the following chart represents the recommended duration of treatment for specific infectionsbased on guidelines published by or with the Infectious Diseases Society of America. In situations where the IDSA didnot have guidelines, the most relevant national group was sought for guidance (e.g. Society of Critical Medicine forsepsis recommendations). This chart is intended to serve as a guide for the appropriate duration of treatment and itsuse should be combined with clinical judgment taking into account patient specific responses to therapy. InfectiousDisease service is often consulted for complex patients, especially those with aspergillosis, blastomycosis, andcryptococcal disease and duration of antimicrobial therapy can vary widely from the recommendations. For electronicaccess to the guidelines, please visit http://www.idsociety.org.InfectionLength of TherapyCatheter related infection 1 Last Guideline: 2009 / Projected Update: Fall 2010Short-term central or peripheral infection,NEG BCx, cath tip POS with S. aureusShort-term central orperipheral infection,POS BCx, cath tipPOS, uncomplicatedLong-term central orport, POS BCx,uncomplicatedCoNS5-7 days5-7 days PLUS remove catheter or10-14 days PLUS abx lock without catheter removalS. aureus ≥ 14 days PLUS remove catheterEnterococcus orGram neg bacilli7-14 days PLUS remove catheterCandida spp. 14 days after first NEG BCx PLUS remove catheterCoNS10-14 days PLUS abx lock without catheter removalS. aureus 4-6 weeks PLUS remove catheterEnterococcus7-14 days PLUS abx lock without catheter removal(consider catheter removal if deterioration or persistent bacteremia)7-14 days PLUS remove catheter orGram neg bacilli 10-14 days PLUS abx lock without catheter removal(remove if no response and r/o endocarditis)Candida spp. 14 days after first NEG BCx PLUS remove catheterTunnel infection/Port abscess, POS BCx,complicated7-10 days PLUS remove catheterSeptic thrombosis, endocarditis,osteomyelitis, POS BCx, complicated4-6 weeks PLUS remove catheter6-8 weeks PLUS remove catheter for osteomyelitisTunneled HD cath, CoNS orresolution of Gram neg bacilli10-14 days PLUS abx lock with or without guidewire exchangedbacteremia or S. aureus 3 weeks (with negative TEE) PLUS remove catheterfungemia and fever C. albicans 14 days after first NEG BCx and guidewire exchangePersistent bacteremia or fungemia andfever4-6 weeks PLUS remove catheterClostridium difficile 2Initial episode, mildor moderateInitial episode,severeInitial episode,severe,complicatedFirst recurrenceSecond recurrenceWBC < 15,000 andSCr < 1.5 times thepremorbid levelWBC > 15,000 anda SCr > 1.5 timesthe premorbid levelHypotension orshock, ileus,megacolonInitial episode, mild or moderateInitial episode, severeInitial episode, severe, complicatedLast Guideline: 2010 / Projected Update: UnknownSame as initial episodeVancomycin in a tapered and/or pulsed regimen (example: vancomycin125mg po four times per day for 10-14 days, then 125mg po BID for 7 days,then 125mg po daily for 7 days, and then 125mg po every 2 or 3 days for 2-8weeks)Diabetic foot ulcer 3 Last Guideline: 2004 / Projected Update: Summer 2010Soft Tissue Only1-2 weeks: mild (>2 manifestations of inflammation, cellulitis
- Page 2 and 3:
PREFACEThe Antimicrobial Use Guidel
- Page 4 and 5:
Antimicrobial Cost Table (Cost info
- Page 6 and 7:
Summary of Antibiotic Order Form: S
- Page 8:
LUNGS/PULMONARYCommunity-Acquired P
- Page 12 and 13:
PART I: BY DRUGABACAVIRFor up-to-da
- Page 14 and 15:
constructed systemic-pulmonary shun
- Page 16 and 17:
AMPICILLIN/SULBACTAM (Unasyn ® )Us
- Page 18 and 19:
ATOVAQUONE/PROGUANIL (Malarone ® )
- Page 20 and 21:
CEFAZOLINUsual DoseAdult: Moderate/
- Page 22 and 23:
CommentsDose adjustment required fo
- Page 24 and 25:
1. Typhoid fever. (NOTE: Third-gene
- Page 26 and 27:
-Dutasteride-Eltrombopag-Theophylli
- Page 28 and 29:
CLINDAMYCINUsual DoseAdult: 600-900
- Page 30 and 31:
DAPTOMYCINInfectious Disease approv
- Page 32 and 33:
Concurrent administration with peni
- Page 34 and 35:
• Cisapride (contraindicated) •
- Page 36 and 37:
• Oral contraceptives/hormones -
- Page 38 and 39:
Synergy in infective endocarditis a
- Page 40 and 41:
• Colchicine • Indinavir • Ta
- Page 42 and 43:
• Donepezil • Pioglitazone• D
- Page 44 and 45:
with linezolid should be considered
- Page 46 and 47:
4. Life-threatening Gram-negative i
- Page 48 and 49:
MOXIFLOXACINLevofloxacin and moxifl
- Page 50 and 51:
Indications1. Uncomplicated cystiti
- Page 52 and 53:
CommentsDose adjustment required fo
- Page 54 and 55:
PIPERACILLIN/TAZOBACTAM (Zosyn ® )
- Page 56 and 57:
PRIMAQUINEUsual DoseAdult: Malaria
- Page 58 and 59:
RIFABUTINUsual DoseAdult (150 mg ca
- Page 60 and 61:
• Chloramphenicol • Leflunomide
- Page 62 and 63:
SULFISOXAZOLENo longer available as
- Page 64 and 65:
TICARCILLIN/CLAVULANATE (Timentin
- Page 66 and 67:
2. Recurrent urinary tract infectio
- Page 68 and 69:
VANCOMYCINUsual DoseAdult: 1 g Q12H
- Page 70 and 71:
Careful monitoring of patients usin
- Page 72 and 73:
APPENDIX B: UWHC SURGICAL ANTIMICRO
- Page 74 and 75:
GI:Appendectomy 3Anaerobic organism
- Page 76 and 77:
VascularLIKELYPATHOGENS• ANTIMICR
- Page 78 and 79:
Cleanorthopedicprocedures(other)Sta
- Page 80 and 81:
APPENDIX C: THERAPY FOR TUBERCULOSI
- Page 82 and 83: p-Aminosalicylic acid(PAS)Granules
- Page 84 and 85: Appendix D: UNIVERSITY OF WISCONSIN
- Page 86 and 87: Appendix E: UWHC Guidelines for the
- Page 88 and 89: B. Antifungal Prophylaxis for BMT a
- Page 90 and 91: D. Cost ComparisonDrugAmphotericin
- Page 92 and 93: 17. Maertens J, Glasmacher A, Herbr
- Page 94 and 95: 47. Courtney R, Wexler D, Radwanski
- Page 96 and 97: 2.1.7 Patient is without placement
- Page 98 and 99: Medications Approved for Parenteral
- Page 100 and 101: APPENDIX G: Serum Drug Concentratio
- Page 102 and 103: APPENDIX H: Guidelines for Monitori
- Page 104 and 105: 1. Patients with large volumes of d
- Page 106 and 107: 16. Tsuji B, Rybak MJ. The influenc
- Page 108 and 109: APPENDIX I: Infectious Diseases App
- Page 110 and 111: APPENDIX J: UWHC Guidelines For the
- Page 112 and 113: with aztreonam and other beta-lacta
- Page 114 and 115: D. Side Chains1.2.5. The prescriber
- Page 116 and 117: 14. Pichichiro ME. Use of selected
- Page 118 and 119: Appendix KUWHC Guidelines for Cost-
- Page 120 and 121: sulfa and can be prescribed topatie
- Page 122 and 123: superinfection: amoxicillin 1 g PO
- Page 124 and 125: 17. Smucny J, Fahey T, Becker L, Gl
- Page 126 and 127: Appendix M: Guidelines for the Prop
- Page 128 and 129: D. CategorizationPatients should be
- Page 130 and 131: Empiric coverage for Enterococcus i
- Page 134 and 135: Bone or JointEndocarditis 4Streptoc
- Page 136 and 137: Candidemia or candidiasis 11Non-neu
- Page 138 and 139: 11. Pappas PG, Kauffman CA, Andes D
- Page 140 and 141: piperacillin/tazobactam. There were
- Page 142 and 143: D. Dose of Antibiotic1. Piperacilli
- Page 144 and 145: TNAVasopressinVoriconazoleMeropenem
- Page 146 and 147: pretreatment with an H1-histamine b
- Page 148 and 149: formal consult is not required, but
- Page 150: K. References1.0 Bliziotis IA, Ples